Opiant Pharmaceuticals (OPNT) 10-Q10 Jun 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Apr. 30, 2014	Jun. 06, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Lightlake Therapeutics Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--07-31	'
Amendment Flag	'false	'
Entity Central Index Key	'0001385508	'
Entity Filer Category	'Smaller Reporting Company	'
Document Period End Date	30-Apr-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Common Stock, Shares Outstanding	'	177,907,394

Balance_Sheets

Balance Sheets (USD $)	Apr. 30, 2014	Jul. 31, 2013
Current assets	'	'
Cash and cash equivalents	$180,827	$598,623
Prepaid insurance	41,650	21,250
Total current assets	222,477	619,873
Other assets	'	'
Patents and patent applications (net of accumulated amortization of $5,224 at April 30, 2014 and $4,270 at July 31, 2013)	22,226	23,180
Total assets	244,703	643,053
Current liabilities	'	'
Accounts payable and accrued liabilities	19,060	40,767
Accrued salaries and wages	1,131,893	457,636
Due to related party	350,000	350,000
Convertible notes payable, net of debt discounts	'	25,000
Derivative liability	'	9,666
Total current liabilities	1,500,953	883,069
Deferred revenue	1,003,500	750,000
Total liabilities	2,504,453	1,633,069
Stockholders' deficit	'	'
Common stock; par value $0.001; 200,000,000 shares authorized; 178,207,278 shares issued and outstanding at April 30, 2014 and 164,699,973 shares issued and outstanding at July 31, 2013	178,206	164,700
Additional paid-in capital	39,735,580	33,695,679
Accumulated deficit during the development stage	-42,173,536	-34,850,395
Total stockholders' deficit	-2,259,750	-990,016
Total liabilities and stockholders' deficit	$244,703	$643,053

Balance_Sheets_Parentheticals

Balance Sheets (Parentheticals) (USD $)	Apr. 30, 2014	Jul. 31, 2013
Balance Sheets [Abstract]	'	'
Patents and patent applications, accumulated amortization (in Dollars)	$5,224	$4,270
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, share authorized (in Shares)	200,000,000	200,000,000
Common stock, share issued (in Shares)	178,207,278	164,699,973
Common stock, shares outstanding (in Shares)	178,207,278	164,699,973

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		9 Months Ended		106 Months Ended
Statements of Operations (USD $)	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014
Statements of Operations [Abstract]	'	'	'	'	'
Revenues	'	'	'	'	'
Operating expenses	'	'	'	'	'
General and administrative	494,455	544,650	7,035,800	7,369,472	40,645,103
Research and development	52,486	35,000	141,882	158,679	930,721
Mineral interests	'	'	'	'	39,015
Total operating expenses	546,941	579,650	7,177,682	7,528,151	41,614,839
Loss from operations	-546,941	-579,650	-7,177,682	-7,528,151	-41,614,839
Other income (expense)	'	'	'	'	'
Interest expense	-7,254	-177,186	-139,043	-431,940	-753,477
Change in derivative	'	'	-27,067	81,804	130,966
Gain on debt settlement/forgiveness	'	'	20,651	'	63,814
Total other income (expense)	-7,254	-177,186	-145,459	-350,136	-558,697
Loss before provision for income taxes	-554,195	-756,836	-7,323,141	-7,878,287	-42,173,536
Provision for income taxes	'	'	'	'	'
Net loss	($554,195)	($756,836)	($7,323,141)	($7,878,287)	($42,173,536)
Loss per common share:	'	'	'	'	'
Basic and diluted	$0	($0.01)	($0.04)	($0.06)	'
Weighted average common shares outstanding	'	'	'	'	'
Basic and diluted	177,929,385	132,928,865	173,631,615	132,928,865	'

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity (Deficit) (USD $)	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Deficit During the Development Stage [Member]
Balance at Jul. 31, 2005	'	'	'	'
Balance, shares at Jul. 31, 2005	'	'	'	'
Common shares issued for cash during March 2006 at $0.001 per share	5,000	5,000	'	'
Common shares issued for cash during March 2006 at $0.001 per share, shares	'	5,000,000	'	'
Common shares issued for cash during March 2006 at $0.01 per share	13,000	1,300	11,700	'
Common shares issued for cash during March 2006 at $0.01 per share, shares	'	1,300,000	'	'
Common shares issued for cash during April 2006 at $0.01 per share	7,500	75	7,425	'
Common shares issued for cash during April 2006 at $0.01 per share, shares	'	75,000	'	'
Common shares issued for cash during May 2006 at $0.01 per share	30,000	150	29,850	'
Common shares issued for cash during May 2006 at $0.01 per share, shares	'	150,000	'	'
Net income (loss)	-32,125	'	'	-32,125
Balance at Jul. 31, 2006	23,375	6,525	48,975	-32,125
Balance, shares at Jul. 31, 2006	'	6,525,000	'	'
Net income (loss)	-33,605	'	'	-33,605
Balance at Jul. 31, 2007	-10,230	6,525	48,975	-65,730
Balance, shares at Jul. 31, 2007	'	6,525,000	'	'
Net income (loss)	-17,924	'	'	-17,924
Balance at Jul. 31, 2008	-28,154	6,525	48,975	-83,654
Balance, shares at Jul. 31, 2008	'	6,525,000	'	'
Net income (loss)	28,444	'	'	28,444
Balance at Jul. 31, 2009	290	6,525	48,975	-55,210
Balance, shares at Jul. 31, 2009	'	6,525,000	'	'
Forward Stock Split : 20 for 1	'	130,500	-130,500	'
Forward Stock Split : 20 for 1, shares	'	130,500,000	'	'
Stock issued for acquisition of patent	20,333	20,333	'	'
Stock issued for acquisition of patent, shares	'	20,333,333	'	'
Stock issued for services	1,358,800	4,150	1,354,650	'
Stock issued for services, shares	'	4,150,000	'	'
Cancellation of shares	'	-100,000	100,000	'
Cancellation of shares, shares	'	-100,000,000	'	'
Net income (loss)	-2,016,710	'	'	-2,016,710
Balance at Jul. 31, 2010	-637,287	61,508	1,373,125	-2,071,920
Balance, shares at Jul. 31, 2010	'	61,508,333	'	'
Warrants issued for acquisition of patent	7,117	'	7,117	'
Sales of common stock	3,078,020	5,640	3,072,380	'
Sales of common stock, shares	'	5,640,000	'	'
Stock issued for services	6,118,170	9,828	6,108,342	'
Stock issued for services, shares	'	9,828,000	'	'
Stock based compensation from issuance of stock options	2,550,000	'	2,550,000	'
Net income (loss)	-11,454,537	'	'	-11,454,537
Balance at Jul. 31, 2011	-338,517	76,976	13,110,964	-13,526,457
Balance, shares at Jul. 31, 2011	'	76,976,333	'	'
Sales of common stock	802,929	8,439	794,490	'
Sales of common stock, shares	'	8,438,572	'	'
Stock issued for services	10,048,857	37,556	10,011,301	'
Stock issued for services, shares	'	37,555,668	'	'
Conversion of Convertible Notes Payable to Common Stock	100,000	3,332	96,668	'
Conversion of Convertible Notes Payable to Common Stock, shares	'	3,332,843	'	'
Cancellation of shares	'	-220	220	'
Cancellation of shares, shares	'	-220,000	'	'
Stock based compensation from issuance of stock options	752,760	'	752,760	'
Stock based compensation from issuance of stock warrants	161,700	'	161,700	'
Net income (loss)	-12,146,447	'	'	-12,146,447
Balance at Jul. 31, 2012	-618,718	126,083	24,928,103	-25,672,904
Balance, shares at Jul. 31, 2012	'	126,083,416	'	'
Sales of common stock	55,000	917	54,083	'
Sales of common stock, shares	'	916,666	'	'
Stock issued for services	937,353	12,266	925,087	'
Stock issued for services, shares	'	12,265,568	'	'
Conversion of Convertible Notes Payable to Common Stock	802,412	25,334	777,078	'
Conversion of Convertible Notes Payable to Common Stock, shares	'	25,334,323	'	'
Issuance of Common Stock as Deferred Financing Cost	13,500	100	13,400	'
Issuance of Common Stock as Deferred Financing Cost, shares	'	100,000	'	'
Stock based compensation from issuance of stock options	3,610,362	'	3,610,362	'
Stock based compensation from issuance of stock warrants	3,261,000	'	3,261,000	'
Forgiveness of debt by related party	126,566	'	126,566	'
Net income (loss)	-9,177,491	'	'	-9,177,491
Balance at Jul. 31, 2013	-990,016	164,700	33,695,679	-34,850,395
Balance, shares at Jul. 31, 2013	164,699,973	164,699,973	'	'
Derivative liability	-337,413	'	-337,413	'
Settlement of derivative liability	506,574	'	506,574	'
Stock issued for services	213,967	4,186	209,781	'
Stock issued for services, shares	'	4,186,692	'	'
Conversion of Convertible Notes Payable to Common Stock	8,056	333	7,723	'
Conversion of Convertible Notes Payable to Common Stock, shares	'	333,333	'	'
Stock issued due to exercise of warrants	'	8,987	-8,987	'
Stock issued due to exercise of warrants, shares	8,987,280	8,987,280	'	'
Stock based compensation from issuance of stock options	5,662,223	'	5,662,223	'
Net income (loss)	-7,323,141	'	'	-7,323,141
Balance at Apr. 30, 2014	($2,259,750)	$178,206	$39,735,580	($42,173,536)
Balance, shares at Apr. 30, 2014	178,207,278	178,207,278	'	'

Statement_of_Stockholders_Equi1

Statement of Stockholders' Equity (Deficit) (Parentheticals) (USD $)	12 Months Ended
	Jul. 31, 2009	Jul. 31, 2006	Jul. 31, 2006	Jul. 31, 2006	Jul. 31, 2006
	Jul. 31, 2009	March 2006 at $0.001 per share	March 2006 at $0.01 per share	April 2006 at $0.01 per share	May 2006 at $0.01 per share
Common stock issued, value per share (in Dollars per share)	'	$0.00	$0.01	$0.01	$0.01
stock split	'20 for 1	'	'	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	9 Months Ended		106 Months Ended
Statements of Cash Flows (USD $)	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014
Cash flows provided by (used in) operating activities	'	'	'
Net loss	($7,323,141)	($7,878,287)	($42,173,536)
Adjustments to reconcile net loss to net cash used by operating activities:	'	'	'
Amortization	954	1,029	5,224
Issuance of common stock for services	213,967	802,074	18,677,147
Issuance of common stock as deferred financing costs	'	'	13,500
Stock based compensation from issuance of options	5,662,223	711,833	12,575,345
Stock based compensation from issuance of warrants	'	152,450	3,422,700
Accreted interest on debt discounts	132,428	94,424	613,193
Gain on debt settlement/forgiveness	-20,651	'	-20,651
Change in derivative	27,067	46,019	-130,966
Changes in assets and liabilities:	'	'	'
(Increase) in prepaid insurance	-20,400	29,750	-41,650
Increase (decrease) in accounts payable	-21,707	16,392	19,060
Increase in accrued salaries and wages	677,964	216,671	1,135,600
Net cash used by operating activities	-671,296	-5,807,645	-5,905,034
Cash flows provided by (used in) investing activities	'	'	'
Cash flows provided by (used in) financing activities	'	'	'
Borrowings from related parties	'	350,000	922,587
Borrowings on convertible notes payable	'	246,837	604,500
Payments to related parties on notes payable	'	-11,626	-436,175
Investment received in exchange for royalty agreement	253,500	600,000	1,003,500
Issuance of common stock for cash	'	55,000	3,991,449
Net cash provided from financing activities	253,500	1,240,211	6,085,861
Net increase (decrease) in cash and cash equivalents	-417,796	-4,567,434	180,827
Cash and cash equivalents, beginning of period	598,623	20,423	'
Cash and cash equivalents, end of period	180,827	-4,547,011	180,827
Supplemental disclosure	'	'	'
Interest paid during the period	139,043	431,940	403,523
Taxes paid during the period	'	'	'
Non-Cash Transactions	'	'	'
Conversion of debt to equity	8,056	399,857	378,900
Debt discounts attributable to derivative valuation	132,428	152,078	452,205
Settlement of derivative liability	506,574	'	506,574
Cashless exercise of warrants	8,988	'	8,988
Derivative liability	$337,413	'	$337,413

Organization_Description_of_Bu

Organization, Description of Business, and Basis of Presentation	9 Months Ended
	Apr. 30, 2014
Organization, Description of Business, and Basis of Presentation [Abstract]	'
Organization, Description of Business, and Basis of Presentation	'
		1	Organization, Description of Business, and Basis of Presentation

	Business Organization
	Lightlake Therapeutics Inc., (formerly known as Madrona Ventures, Inc.) (the "Company"), was originally incorporated in the State of Nevada on June 21, 2005. On September 16, 2009, the Company changed its name to Lightlake Therapeutics Inc. The Company's fiscal year end is July 31.

	Development Stage Entity
	The Company is a development stage company as defined by ASC 915, Development Stage Entities. The Company is still devoting substantially all of its efforts on establishing the business and its planned principal operations have not commenced. All losses accumulated since inception have been considered as part of the Company's development stage activities.

	Basis of Presentation

	The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, these condensed financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These financial statements should be read in conjunction with the financial statements for the year ended July 31, 2013 and notes thereto and other pertinent information contained in the Form 10-K the Company has filed with the Securities and Exchange Commission (the "SEC").

	The results of operations for the nine months ended April 30, 2014 are not necessarily indicative of the results for the full fiscal year ending July 31, 2014.

Going_Concern

Going Concern	9 Months Ended
	Apr. 30, 2014
Going Concern [Abstract]	'
Going Concern	'
		2	Going Concern

	The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, the Company has incurred significant losses and is dependent on obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain the necessary funding it could cease operations as a new enterprise. This raises substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might result from this uncertainty

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Apr. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
		3	Summary of Significant Accounting Policies

	Use of estimates
	The Company prepares its financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

	Fair Value of Financial Instruments
	FASB Accounting Standards Codification (ASC) 820 "Fair Value Measurements and Disclosures" (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

	The three levels of the fair value hierarchy are described below:

	Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

	Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

	Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

	The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts receivable, other current assets, accounts payable, accrued compensation and accrued expenses. The fair value of the Company's notes payable is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value.

	As of April 30, 2014, the convertible note was converted to equity and the derivative warrants were either exchanged for common stock or no longer required derivative treatment as a result of the note conversion. Consequently, at April 30, 2014, derivative liabilities have a balance of zero. The derivative instruments were marked to market at settlement dates and the corresponding value of the derivative liabilities of $506,574 was credited to additional paid in capital.

	The following table presents the derivative financial instruments, the Company's only financial liabilities measured and recorded at fair value on the Company's consolidated balance sheets on a recurring basis, and their level within the fair value hierarchy as of July 31, 2013:

			Amount			Level 1			Level 2		Level 3
	Embedded conversion derivative liability		$	9,666		$	-		$	-	$	9,666
	Warrant derivative liabilities			-			-			-		-
	Total		$	9,666		$	-		$	-	$	9,666

	The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs:

	Balance at July 31, 2013		$	9,666
	Fair value of warrant derivative liabilities at issuance			469,841
	Settlement of derivative liability			(506,574	)
	Unrealized derivative loss included in other expense			27,067
	Balance at April 30, 2014		$	-

	The fair value of the derivative liabilities are calculated at inception and the Company records a derivative liability for the calculated value. Changes in the fair value of the derivative liabilities are recorded in other income (expense) in the statements of operations.

	The derivative warrants were valued using the Black Scholes option pricing model using the following assumptions:

			At settlement			31-Jul-13
			dates			31-Jul-13
	Market value of stock on measurement date			$0.043 - $0.05		$	0.0289
	Risk-free interest rate			0.77 - 0.96	%		0.11	%
	Dividend yield			0	%		0	%
	Volatility factor			169 - 217	%		76.9	%
	Term			2.8 - 3.9 years			0.493 years

	Reclassification
	Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses.

	Recently Issued Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.

Revision_of_Prior_Period_Amoun

Revision of Prior Period Amounts	9 Months Ended
Revision of Prior Period Amounts	Apr. 30, 2014
Revision of Prior Period Amounts [Abstract]	'
Revision of Prior Period Amounts	'
		4	Revision of Prior Period Amounts

	In preparing the Company's financial statements for the quarter ended October 31, 2013, the Company discovered and corrected errors related to the accounting of stock options issued to officers and a director in prior years which were either fully vested at the date of grant or with a vesting term ranging up to 9 years. The prior period financial statements amortized these costs over the contractual term as opposed to the vesting period. This error resulted in a misstatement in stock based compensation expense for the three and nine months ended April 30, 2014 of ($205,106) and $2,098,270, respectively.

	Additionally, 72,500,000 in warrants were issued to officers on December 31, 2012 as part of their employment agreements. These warrants vested on that date and were determined to have a fair value of $3,261,000. During the three and nine months ended April 30, 2013, the Company recognized an expense related to these warrants of $72,450 and $152,450, respectively. Therefore, there was a net under (over)statement in stock-based compensation expense of ($72,450) and $3,108,550 for the three and nine months ended April 30, 2014, respectively.

	In accordance with SEC Staff Accounting Bulletin Nos. 99 and 108 ("SAB 99 and SAB 108"), the Company evaluated these errors and, based on an analysis of quantitative and qualitative factors, determined that they were immaterial to each of the reporting periods affected and, therefore, amendment of previously filed reports with the Securities and Exchange Commission was not required. However, if the adjustments to correct the cumulative effect of the aforementioned errors had been recorded in the nine months ended April 30, 2014, the Company believes the impact would have been significant to the current quarter and would impact comparisons to prior periods. Therefore, as permitted by SAB 108, the Company revised in the current filing previously reported quarterly results during the three and nine months ended April 30, 2013.

	The impact of the above errors to the statement of operations for the nine months ended April 30, 2013 are as follows:

			As previously
			reported			Adjustments				As revised

	Revenues			-			-				-
	Operating expenses
	General and administrative			2,162,652			5,206,820				7,369,472
	Research and development			158,679			-				158,679

	Total operating expenses			2,321,331			5,206,820				7,528,151

	Other income (expense)
	Interest expense			(431,940	)		-				(431,940	)
	Change in derivative			81,804			-				81,804
	Debt forgiveness			-			-				-

	Total other income (expense)			(350,136	)		-				(350,136	)

	Income (loss) before provision for income taxes			(2,671,467	)		5,206,820				(7,878,287	)
	Provision for income taxes			-			-				-

	Net income (loss)			(2,671,467	)		5,206,820				(7,878,287	)

	Loss per common share:
	Basic and diluted		$	(0.01	)		-			$	(0.06	)

	Weighted average common shares outstanding
	Basic and diluted			132,928,865			-				132,928,865

	The above errors did not impact previously reported amounts of net cash used in operating activities, investing activities and financing activities as reported in the statements of cash flows for the nine months ended April 30, 2013.

	The impact of the above errors to the statement of operations for the three months ended April 30, 2013 are as follows:

			As previously
			reported			Adjustments				As revised

	Revenues			-			-				-
	Operating expenses
	General and administrative			822,206			(277,556	)			544,650
	Research and development			35,000			-				35,000

	Total operating expenses			857,206			(277,556	)			579,650

	Other income (expense)
	Interest expense			(177,186	)		-				(177,186	)
	Change in derivative			-			-				-
	Debt forgiveness			-			-				-

	Total other income (expense)			(177,186	)		-				(177,186	)

	Income (loss) before provision for income taxes			(1,034,392	)		(277,556	)			(756,836	)
	Provision for income taxes			-			-				-

	Net income (loss)			(1,034,392	)		(277,556	)			(756,836	)
Loss per common share:
Basic and diluted		$	(0.00	)		-			$	(0.01	)

Weighted average common shares outstanding
Basic and diluted			132,928,865			-				132,928,865

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Apr. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
		5	Related Party Transactions

	At April 30, 2014 and July 31, 2013, the Company had loans outstanding with its three officers and a director in the amount of $350,000. During December 2012, funds were advanced as per agreements dated December 18, 2012 in the amount of $350,000 and at an interest rate of 6.0% per annum to cover the short-term cash needs of the Company. The agreements were amended on December 16, 2013 to extend the final maturity date to January 6, 2015 and increased the interest rate to 8.5% per annum. In the event that at least one-third and one-ninth of the amount due plus interest is not repaid by September 30, 2014 and December 25, 2014, respectively, certain penalties will apply. The Company has evaluated the modification of the loans under FASB ASC 470-50 and determined that the modification was not substantial and therefore did not constitute a debt extinguishment.

Deferred_Revenue

Deferred Revenue	9 Months Ended
	Apr. 30, 2014
Deferred Revenue [Abstract]	'
Deferred Revenue	'
		6	Deferred Revenue

	On December 17, 2013, the Company entered into an agreement and subsequently received additional funding totaling $250,000 for use by the Company for any purpose. In exchange for this funding, the Company agreed to provide the investor with a 0.5% interest in the Company's Binge Eating Disorder treatment product and pay the investor 0.5% of the net profit generated from this treatment in perpetuity. Net profit is defined as the pre-tax profit generated from the product after the deduction of all expenses incurred by and payments made by the Company in connection with the product, including but not limited to an allocation of Company overhead. If the product is not approved by the U.S. Food and Drug Administration within 36 months the investor will have a sixty day option to receive 3,125,000 shares of common stock in lieu of the 0.5% interest in the product.

	This investment was accounted for as a liability pursuant to current accounting research until such time as the product is approved by the U.S. Food and Drug Administration, at which time it will be recognized as revenue. However, if the milestone is not achieved then the investment will be recorded as additional paid-in capital upon issuance of the common stock.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Apr. 30, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
		7	Stockholders' Equity

	Common Stock

	On August 12, 2013, the Company issued 375,000 shares in exchange for services rendered. The shares issued in this transaction were valued at market and amounted to $15,000.

	On August 28, 2013, the Company issued 500,000 shares in exchange for services rendered. The shares issued in this transaction were valued at market and amounted to $35,000.

	On September 18, 2013, the Company issued 375,000 shares in exchange for services rendered. The shares issued in this transaction were valued at market and amounted to $22,500.

	On October 21, 2013, the Company issued 225,895 shares in exchange for services rendered. The shares issued in this transaction were valued at market and amounted to $9,036.

	On October 25, 2013, the Company issued 334,572 shares in exchange for services rendered. The shares issued in this transaction were valued at market and amounted to $13,382.

	On October 31, 2013, the Company issued 375,000 shares in exchange for services rendered. The shares issued in this transaction were valued at market and amounted to $15,750.

	In November 2013, the Company issued 1,250,000 shares in exchange for services rendered. The shares issued were valued at market and amounted to $66,500.

	On December 23, 2013, the Company issued 375,000 shares in exchange for services rendered. The shares issued in this transaction were valued at market and amounted to $21,750.

	On April 7, 2014, the Company issued 376,225 shares in exchange for services rendered. The shares issued in this transaction were valued at market and amounted to $15,049.

	During the nine months ended April 30, 2014, the Company issued 8,987,280 shares as a result of the cashless exercise of 888,452 warrants.

	Stock Based Compensation
	As required by ASC 718, the Company measures and recognizes compensation expense for all share based payment awards made to the officers and directors based on estimated fair values. Stock based compensation expense recognized in the Statement of Operations for the three and nine months ended April 30, 2014 was $0 and $5,662,223, respectively.

	On August 1, 2013 the Company granted its executive officers cashless stock options to purchase a total of 37,500,000 shares of its common stock at exercise prices ranging from $0.10 to $0.20 per share. These options vested immediately and expire in ten years on July 31, 2023. The Company has valued these options using the Black Scholes option pricing model which resulted in a fair market value of $1,068,750 which has been fully recognized as expense for the nine months ended, April 30, 2014.

	On November 1, 2013 the Company granted its executive officers cashless stock options to purchase a total of 22,500,000 shares of its common stock at exercise prices ranging from $0.06 to $0.10 per share. These options vested immediately and expire in ten years on October 31, 2023. The Company has valued these options using the Black Scholes option pricing model which resulted in a fair market value of $985,500 which has been fully recognized as expense for the nine months ended, April 30, 2014.

	On December 31, 2013 the Company granted its executive officers cashless stock options to purchase a total of 66,500,000 shares of its common stock at exercise prices ranging from $0.06 to $0.10 per share. These options vested immediately and expire in ten years on December 30, 2023. The Company has valued these options using the Black Scholes option pricing model which resulted in a fair market value of $3,591,000 which has been fully recognized as expense for the nine months ended, April 30, 2014.

	The assumptions used in the valuation were as follows:

	Market value of stock on measurement date		$	0.0285-0.054
	Risk-free interest rate			2.24 - 2.99	%
	Dividend yield			0	%
	Volatility factor			438 - 459	%
	Term			10 years

	Stock option activity for nine months ended April 30, 2014 is presented in the table below:

			Number of				Weighted-		Weighted-			Aggregate
			Shares				average		average			Intrinsic
							Exercise		Remaining			Value
							Price		Contractual
									Term
									(years)
	Outstanding at July 31, 2013			76,250,000			$	0.18		5.56		$	-
	Granted			126,500,000			$	0.1		-		$	-
	Forfeited/expired/cancelled			(8,500,000	)		$	0.67		-		$	-
	Outstanding at April 30, 2014			194,250,000			$	0.11		8.11		$	-
	Exercisable at April 30, 2014			156,125,000			$	0.1		8.8		$	-

	Warrants

	Warrant activity for nine months ended April 30, 2014is presented in the table below:

			Number of				Weighted-		Weighted-			Aggregate
			Shares				average		average			Intrinsic
							Exercise		Remaining			Value
							Price		Contractual
							Term
							(years)
Outstanding at July 31, 2013				102,363,691			$	0.23		4.02		$	-
Granted				-			$	-		-		$	-
Exercised			(888,452	)		$	0.5		-		$	-
Outstanding at April 30, 2014			101,475,239			$	0.23		3.52		$	-
Exercisable at April 30, 2014			28,975,239			$	0.42		2.28		$	-

Settlement_of_Convertible_Note

Settlement of Convertible Note Payable	9 Months Ended
	Apr. 30, 2014
Settlement of Convertible Note Payable [Abstract]	'
Settlement of Convertible Note Payable	'
		8	Settlement of Convertible Note Payable

	On January 23, 2014 the Company entered into a settlement of a convertible note payable in the amount of $25,000 and interest of $3,707 through the issuance of 333,333 shares of common stock. This transaction resulted in a gain on the extinguishment of the debt in the amount of $20,651.

Subsequent_Events

Subsequent Events	9 Months Ended
	Apr. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
		9	Subsequent Events

	On May 15, 2014, the Company entered into an agreement and subsequently received funding from an investor in the amount of $300,000 for use by the Company for any purpose, including the research, development, marketing and commercialization of the Company's opioid overdose reversal treatment. In exchange for this funding, the Company agreed to provide the investor with a 1.5% interest in the product and pay the investor 1.5% of the net profit generated from the product used for this treatment after the deduction of all expenses incurred by and payments made by the Company in connection with the product, including but not limited to an allocation of Company overhead. If the product is not introduced to the market and not approved for marketing within 24 months of the date of investment, the investor will have a sixty day option to receive 3,750,000 shares of common stock in lieu of the 1.5% interest in the product.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Apr. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
Use of estimates	'
	Use of estimates
	The Company prepares its financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	FASB Accounting Standards Codification (ASC) 820 "Fair Value Measurements and Disclosures" (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

	The three levels of the fair value hierarchy are described below:

	Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

	Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

	Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

	The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts receivable, other current assets, accounts payable, accrued compensation and accrued expenses. The fair value of the Company's notes payable is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value.

	As of April 30, 2014, the convertible note was converted to equity and the derivative warrants were either exchanged for common stock or no longer required derivative treatment as a result of the note conversion. Consequently, at April 30, 2014, derivative liabilities have a balance of zero. The derivative instruments were marked to market at settlement dates and the corresponding value of the derivative liabilities of $506,574 was credited to additional paid in capital.

	The following table presents the derivative financial instruments, the Company's only financial liabilities measured and recorded at fair value on the Company's consolidated balance sheets on a recurring basis, and their level within the fair value hierarchy as of July 31, 2013:

		Amount			Level 1			Level 2		Level 3
	Embedded conversion derivative liability	$	9,666		$	-		$	-	$	9,666
	Warrant derivative liabilities		-			-			-		-
	Total	$	9,666		$	-		$	-	$	9,666

	The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs:

	Balance at July 31, 2013	$	9,666
	Fair value of warrant derivative liabilities at issuance		469,841
	Settlement of derivative liability		(506,574	)
	Unrealized derivative loss included in other expense		27,067
	Balance at April 30, 2014	$	-

	The fair value of the derivative liabilities are calculated at inception and the Company records a derivative liability for the calculated value. Changes in the fair value of the derivative liabilities are recorded in other income (expense) in the statements of operations.

	The derivative warrants were valued using the Black Scholes option pricing model using the following assumptions:

		At settlement			31-Jul-13
		dates			31-Jul-13
	Market value of stock on measurement date		$0.043 - $0.05		$	0.0289
	Risk-free interest rate		0.77 - 0.96	%		0.11	%
	Dividend yield		0	%		0	%
	Volatility factor		169 - 217	%		76.9	%
	Term		2.8 - 3.9 years			0.493 years
Reclassification	'
	Reclassification
	Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Apr. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
Schedule of Fair Value Measurements	'
	The following table presents the derivative financial instruments, the Company's only financial liabilities measured and recorded at fair value on the Company's consolidated balance sheets on a recurring basis, and their level within the fair value hierarchy as of July 31, 2013:

		Amount			Level 1			Level 2		Level 3
	Embedded conversion derivative liability	$	9,666		$	-		$	-	$	9,666
	Warrant derivative liabilities		-			-			-		-
	Total	$	9,666		$	-		$	-	$	9,666
Summary of Changes in Fair Value	'
	The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs:

	Balance at July 31, 2013	$	9,666
	Fair value of warrant derivative liabilities at issuance		469,841
	Settlement of derivative liability		(506,574	)
	Unrealized derivative loss included in other expense		27,067
	Balance at April 30, 2014	$	-
Schedule of Assumptions Used to Value Warrants	'
	The derivative warrants were valued using the Black Scholes option pricing model using the following assumptions:

		At settlement			31-Jul-13
		dates			31-Jul-13
	Market value of stock on measurement date		$0.043 - $0.05		$	0.0289
	Risk-free interest rate		0.77 - 0.96	%		0.11	%
	Dividend yield		0	%		0	%
	Volatility factor		169 - 217	%		76.9	%
	Term		2.8 - 3.9 years			0.493 years

Revision_of_Prior_Period_Amoun1

Revision of Prior Period Amounts (Tables)	9 Months Ended
Revision of Prior Period Amounts (Tables)	Apr. 30, 2014
Revision of Prior Period Amounts [Abstract]	'
Schedule of Revision of Prior Period Amounts	'
	The impact of the above errors to the statement of operations for the nine months ended April 30, 2013 are as follows:

		As previously
		reported			Adjustments			As revised

	Revenues		-			-			-
	Operating expenses
	General and administrative		2,162,652			5,206,820			7,369,472
	Research and development		158,679			-			158,679

	Total operating expenses		2,321,331			5,206,820			7,528,151

	Other income (expense)
	Interest expense		(431,940	)		-			(431,940	)
	Change in derivative		81,804			-			81,804
	Debt forgiveness		-			-			-

	Total other income (expense)		(350,136	)		-			(350,136	)

	Income (loss) before provision for income taxes		(2,671,467	)		5,206,820			(7,878,287	)
	Provision for income taxes		-			-			-

	Net income (loss)		(2,671,467	)		5,206,820			(7,878,287	)

	Loss per common share:
	Basic and diluted	$	(0.01	)		-		$	(0.06	)

	Weighted average common shares outstanding
	Basic and diluted		132,928,865			-			132,928,865

	The above errors did not impact previously reported amounts of net cash used in operating activities, investing activities and financing activities as reported in the statements of cash flows for the nine months ended April 30, 2013.

	The impact of the above errors to the statement of operations for the three months ended April 30, 2013 are as follows:

		As previously
		reported			Adjustments			As revised

	Revenues		-			-			-
	Operating expenses
	General and administrative		822,206			(277,556	)		544,650
	Research and development		35,000			-			35,000

	Total operating expenses		857,206			(277,556	)		579,650

	Other income (expense)
	Interest expense		(177,186	)		-			(177,186	)
	Change in derivative		-			-			-
	Debt forgiveness		-			-			-

	Total other income (expense)		(177,186	)		-			(177,186	)

	Income (loss) before provision for income taxes		(1,034,392	)		(277,556	)		(756,836	)
	Provision for income taxes		-			-			-

	Net income (loss)		(1,034,392	)		(277,556	)		(756,836	)
	Loss per common share:
	Basic and diluted	$	(0.00	)		-		$	(0.01	)

	Weighted average common shares outstanding
	Basic and diluted		132,928,865			-			132,928,865

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Apr. 30, 2014
Stockholders' Equity [Abstract]	'
Schedule of Assumptions Used in the Valuation	'
	The assumptions used in the valuation were as follows:

	Market value of stock on measurement date	$	0.0285-0.054
	Risk-free interest rate		2.24 - 2.99	%
	Dividend yield		0	%
	Volatility factor		438 - 459	%
	Term		10 years
Schedule of Options and Warrants Outstanding	'
	Stock option activity for nine months ended April 30, 2014 is presented in the table below:

		Number of			Weighted-		Weighted-		Aggregate
		Shares			average		average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term
							(years)
	Outstanding at July 31, 2013		76,250,000		$	0.18		5.56	$	-
	Granted		126,500,000		$	0.1		-	$	-
	Forfeited/expired/cancelled		(8,500,000	)	$	0.67		-	$	-
	Outstanding at April 30, 2014		194,250,000		$	0.11		8.11	$	-
	Exercisable at April 30, 2014		156,125,000		$	0.1		8.8	$	-

	Warrants

	Warrant activity for nine months ended April 30, 2014is presented in the table below:

		Number of			Weighted-		Weighted-		Aggregate
		Shares			average		average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term
							(years)
	Outstanding at July 31, 2013		102,363,691		$	0.23		4.02	$	-
	Granted		-		$	-		-	$	-
	Exercised		(888,452	)	$	0.5		-	$	-
	Outstanding at April 30, 2014		101,475,239		$	0.23		3.52	$	-
	Exercisable at April 30, 2014		28,975,239		$	0.42		2.28	$	-

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Schedule of Fair Value Measurements) (Details) (USD $)	9 Months Ended
	Apr. 30, 2014	Jul. 31, 2013
Liability Derivatives	'	'
Derivative liability	'	$9,666
Settlement of derivative liability	506,574	'
Fair Value, Measurements, Recurring [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	9,666
Fair Value, Measurements, Recurring [Member] \| Conversion Feature [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	9,666
Fair Value, Measurements, Recurring [Member] \| Warrant [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	'
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	'
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| Conversion Feature [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	'
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| Warrant [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	'
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	'
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member] \| Conversion Feature [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	'
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member] \| Warrant [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	'
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	9,666
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Conversion Feature [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	9,666
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Warrant [Member]	'	'
Liability Derivatives	'	'
Derivative liability	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Schedule of Changes in Fair Value) (Details) (Derivative Financial Instruments, Liabilities [Member], USD $)	9 Months Ended
	Apr. 30, 2014
Derivative Financial Instruments, Liabilities [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Balance at July 31, 2013	$9,666
Fair value of warrant derivative liabilities at issuance	469,841
Settlement of derivative liability	-506,574
Unrealized derivative loss included in other expense	27,067
Balance at January 31, 2014	'

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Schedule of Assumptions Used to Compute Fair Value of Warrants) (Details) (Derivative Financial Instruments, Liabilities [Member], USD $)	9 Months Ended	12 Months Ended
	Apr. 30, 2014	Jul. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Market value of stock on measurement date	'	$0.03
Risk-free interest rate	'	0.11%
Dividend yield	0.00%	0.00%
Volatility factor	'	76.90%
Term	'	'5 months 28 days
Minimum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Market value of stock on measurement date	$0.04	'
Risk-free interest rate	0.77%	'
Volatility factor	169.00%	'
Term	'2 years 9 months 18 days	'
Maximum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Market value of stock on measurement date	$0.05	'
Risk-free interest rate	0.96%	'
Volatility factor	217.00%	'
Term	'3 years 10 months 24 days	'

Revision_of_Prior_Period_Amoun2

Revision of Prior Period Amounts (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

106 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Jan. 23, 2014

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Jul. 31, 2013

Apr. 30, 2013

Jul. 31, 2013

Apr. 30, 2013

Errors Related to Accounting for Stock Options [Member]

Errors Related to Accounting for Warrants [Member]

As Previously Reported [Member]

Adjustments [Member]

Vesting period

'9 years

Over (under) statement

($205,106)

$2,098,270

($72,450)

$3,108,550

Awards granted

72,500,000

Vested, fair value

3,261,000

Warrants Issued Value Recognized in Current Year (in Dollars)

152,450

3,422,700

72,450

152,450

920,463

Revenues

Operating expenses

General and administrative

494,455

544,650

7,035,800

7,369,472

40,645,103

822,206

2,162,652

-277,556

5,206,820

Research and development

52,486

35,000

141,882

158,679

930,721

35,000

158,679

Total operating expenses

546,941

579,650

7,177,682

7,528,151

41,614,839

857,206

2,321,331

-277,556

5,206,820

Other income (expense)

Interest expense

-7,254

-177,186

-139,043

-431,940

-753,477

-177,186

-431,940

Change in derivative

-27,067

81,804

130,966

81,804

Debt forgiveness

20,651

63,814

Total other income (expense)

-7,254

-177,186

-145,459

-350,136

-558,697

-177,186

-350,136

Loss before provision for income taxes

-554,195

-756,836

-7,323,141

-7,878,287

-42,173,536

-1,034,392

-2,671,467

277,556

-5,206,820

Provision for income taxes

Net loss

($554,195)

($756,836)

($7,323,141)

($7,878,287)

($42,173,536)

($1,034,392)

($2,671,467)

$277,556

($5,206,820)

Loss per common share:

Basic and diluted

($0.01)

($0.04)

($0.06)

($0.01)

Weighted average common shares outstanding Basic and diluted

177,929,385

132,928,865

173,631,615

132,928,865

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	Apr. 30, 2014	Jul. 31, 2013
Related Party Transaction [Line Items]	'	'
Due to related parties	$350,000	$350,000
Debt instrument, interest rate	8.50%	6.00%

Deferred_Revenue_Details

Deferred Revenue (Details) (USD $)	0 Months Ended
Deferred Revenue (Details) (USD $)	Dec. 17, 2013
Deferred Revenue Arrangement [Line Items]	'
Proceeds from funding agreement	$250,000
Interest in asset	0.50%
Number of shares issuable	3,125,000

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Apr. 07, 2014

Dec. 23, 2013

Oct. 31, 2013

Oct. 25, 2013

Oct. 21, 2013

Sep. 18, 2013

Aug. 28, 2013

Aug. 12, 2013

Nov. 30, 2013

Apr. 30, 2014

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2011

Jul. 31, 2010

Dec. 31, 2013

Nov. 30, 2013

Aug. 31, 2013

Apr. 30, 2014

Oct. 31, 2013

Apr. 30, 2014

Dec. 31, 2013

Nov. 30, 2013

Aug. 31, 2013

Apr. 30, 2014

Dec. 31, 2013

Nov. 30, 2013

Aug. 31, 2013

Apr. 30, 2014

Stock Option [Member]

August 1, 2013 Options [Member]

November 1, 2013 Options [Member]

December 31, 2013 Options [Member]

Minimum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options granted

66,500,000

22,500,000

37,500,000

126,500,000

Options granted, exercise price

$0.10

$0.06

$0.10

$0.20

Expiration period

'10 years

Expiration date

30-Dec-23

31-Oct-23

31-Jul-23

Stock based compensation expense

$5,662,223

$1,068,750

$985,500

$3,591,000

Market value of stock on measurement date

$0.03

$0.05

Risk-free interest rate

2.24%

2.99%

Dividend yield

0.00%

Volatility factor

438.00%

459.00%

Term

'10 years

Stock issued for services, shares

376,225

375,000

334,572

225,895

375,000

500,000

375,000

1,250,000

Stock issued for services

15,049

21,750

15,750

13,382

9,036

22,500

35,000

15,000

66,500

213,967

937,353

10,048,857

6,118,170

1,358,800

Stock issued due to exercise of warrants, shares

8,987,280

Stock issued due to exercise of warrants

Stockholders_Equity_Schedule_o

Stockholders' Equity (Schedule of Outstanding Options and Warrants) (Details) (USD $)	1 Months Ended			9 Months Ended	12 Months Ended
	Dec. 31, 2013	Nov. 30, 2013	Aug. 31, 2013	Apr. 30, 2014	Jul. 31, 2013
WARRANTS [Member]	'	'	'	'	'
Number of Shares	'	'	'	'	'
Outstanding, beginning balance	'	'	102,363,691	102,363,691	'
Granted	'	'	'	'	'
Exercised	'	'	'	-888,452	'
Outstanding, ending balance	'	'	'	101,475,239	102,363,691
Exercisable	'	'	'	28,975,239	'
Weighted- average Exercise Price	'	'	'	'	'
Outstanding	'	'	$0.23	$0.23	'
Granted	'	'	'	'	'
Exercised	'	'	'	$0.50	'
Outstanding	'	'	'	$0.23	$0.23
Exercisable	'	'	'	$0.42	'
Weighted- average Remaining Contractual Term (years)	'	'	'	'	'
Outstanding	'	'	'	'3 years 6 months 7 days	'4 years 7 days
Exercisable	'	'	'	'2 years 3 months 11 days	'
Aggregate Intrinsic Value	'	'	'	'	'
Outstanding	'	'	'	'	'
Exercisable	'	'	'	'	'
OPTIONS [Member]	'	'	'	'	'
Number of Shares	'	'	'	'	'
Outstanding, beginning balance	'	'	76,250,000	76,250,000	'
Granted	66,500,000	22,500,000	37,500,000	126,500,000	'
Forfeited/expired/cancelled	'	'	'	-8,500,000	'
Outstanding, ending balance	'	'	'	194,250,000	76,250,000
Exercisable	'	'	'	156,125,000	'
Weighted- average Exercise Price	'	'	'	'	'
Outstanding	'	'	$0.18	$0.18	'
Granted	'	'	'	$0.10	'
Forfeited/expired/cancelled	'	'	'	$0.67	'
Outstanding	'	'	'	$0.11	$0.18
Exercisable	'	'	'	$0.10	'
Weighted- average Remaining Contractual Term (years)	'	'	'	'	'
Outstanding	'	'	'	'8 years 1 month 10 days	'5 years 6 months 22 days
Exercisable	'	'	'	'8 years 9 months 18 days	'
Aggregate Intrinsic Value	'	'	'	'	'
Outstanding	'	'	'	'	'
Exercisable	'	'	'	'	'

Settlement_of_Convertible_Note1

Settlement of Convertible Note Payable (Details) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended		106 Months Ended
Settlement of Convertible Note Payable (Details) (USD $)	Jan. 23, 2014	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014
Settlement of Convertible Note Payable [Abstract]	'	'	'	'	'	'
Amount of debt converted	$25,000	'	'	$8,056	$399,857	$378,900
Interest paid in common stock	3,707	'	'	'	'	'
Number of shares issued	333,333	'	'	'	'	'
Gain on debt settlement/forgiveness	$20,651	'	'	$20,651	'	$63,814

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	0 Months Ended
	Dec. 17, 2013	15-May-14
	Dec. 17, 2013	Subsequent Event [Member]
Subsequent Event [Line Items]	'	'
Proceeds from funding agreement	$250,000	$300,000
Interest in asset	0.50%	1.50%
Number of shares issuable	3,125,000	3,750,000